Summary
This study aims to assess how a new test (called ArteraAI) that uses artificial intelligence (AI) to analyse prostate tumour samples to predict patient outcomes and suitable treatment options impacts the treatment recommendations that doctors make for their patients with prostate cancer.
Who is it for?
You may be eligible for this study if you are an adult older than 18 years of age, you have been diagnosed with a localised intermediate risk prostate cancer (one or more tumours) and you are scheduled to undergo initial curative radiation therapy treatment for your cancer.
Study details
All participants who choose to enrol in this study will have a sample of their prostate cancer assessed using a new test, ArteraAI, that uses AI and a specialised computer algorithm to analyse the characteristics of their specific cancer.
The ArteraAI test will use previously collected tumour samples so that participants will not need to provide further tissue for this study. Depending upon the results of the ArteraAI test, participants may have their cancer treatment plan changed to include or stop use of androgen deprivation therapy or ADT (testosterone blocking drugs).
A subgroup of participants will also be followed up at 5 years after they have undergone the ArteraAI test to check their Prostate Specific Antigen (PSA) levels noted in their medical records. PSA is collected as part of normal care follow-up for prostate cancer, therefore participants won't need an additional blood test for this.
It is hoped this research will determine whether use of the ArteraAI test helps doctors to make more informed treatment recommendations for patients with prostate cancer. If the ArteraAI test is found to be useful and the costs associated are not prohibitive to publicly-funded medical care, use of the test may be expanded to a greater number of cancer treatment clinics to assist a greater number of patients with prostate cancer.